News

Applied Clinical Trials Online49m
Novo Nordisk’s Sogroya Demonstrates Favorable Outcomes in Phase III Trial for Children’s Growth Disorders
The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...